Back to Authors

Costello, Brian A.

https://orcid.org/0000-0003-1753-5928

A5073960684 | I1330342723

Mayo Clinic

Citations 155

A molecular and clinico-pathological model for predicting abiraterone acetate/prednisone (AA/P) efficacy in metastatic castrate resistant prostate cancer (mCRPC).

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 5056-5056

10.1200/jco.2015.33.15_suppl.5056

Association of germline variation with androgen ablation (AA) failure in advanced hormone-sensitive prostate cancer (HSPC).

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e16117-e16117

10.1200/jco.2015.33.15_suppl.e16117

Variation in TRMT11 gene as a prognostic marker in advanced-stage castrate-resistant prostate cancer (CRPC) patients.

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e16114-e16114

10.1200/jco.2015.33.15_suppl.e16114

Phase II efficacy trial of pazopanib in non-clear cell metastatic renal cell carcinoma (PINCR trial).

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: TPS4606-TPS4606

10.1200/jco.2014.32.15_suppl.tps4606

Chemotherapy for lung cancer in patients on renal replacement therapy: The Mayo Clinic experience.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e20569-e20569

10.1200/jco.2016.34.15_suppl.e20569

Genetic variation in sex hormone receptor genes and association with enzalutamide response in metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e16606-e16606

10.1200/jco.2016.34.15_suppl.e16606

Prognostic impact of genetic variation in steroidogenic enzymes in advanced stage prostate cancer.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e16605-e16605

10.1200/jco.2016.34.15_suppl.e16605

Association of CYP17A1 single nucleotide polymorphism (SNP) with response to abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e16603-e16603

10.1200/jco.2016.34.15_suppl.e16603

Prospective front-line management patterns in the Real World Metastatic Renal Cell Cancer (MaRCC) Registry.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e16097-e16097

10.1200/jco.2016.34.15_suppl.e16097

Deferred systemic therapy (DST) in the prospective metastatic renal cell cancer (MaRCC) registry.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e16084-e16084

10.1200/jco.2016.34.15_suppl.e16084